Michael M. Pham, M.D.

Closed for Enrollment

• A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients with Scleroderma−Related Interstitial Lung Disease Scottsdale/Phoenix, Ariz.

  The purpose of this study is to evaluate the safety and tolerability of ixazomib in patients with scleroderma.

• A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Scottsdale/Phoenix, Ariz.

  The purpose of this study is to evaluate the effectiveness and safety of KD025 to treat Diffuse Cutaneous Systemic Sclerosis.

• A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy And Safety Study Of At Least 48 Weeks Of Oral BI 685509 Treatment In Adults With Early Progressive Diffuse Cutaneous Systemic Sclerosis Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

  The purpose of this study is to find out whether BI 685509 helps people with scleroderma who have symptoms due to lung fibrosis or vascular problems.